3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer - Related Studies

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer

This study is ongoing, but not recruiting participants.

Study NCT00075504. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Extrahepatic Bile Duct Cancer
		Gallbladder Cancer

2	Additional conditions recognized in this trial
		Bile Duct Neoplasms
		Gallbladder Neoplasms

3	More general conditions related to this trial
		Bile Duct Diseases
		Biliary Tract Diseases
		Biliary Tract Neoplasms
		Digestive System Diseases
		Digestive System Neoplasms
		Gallbladder Diseases
		Neoplasms
		Neoplasms by Site

4	Interventions listed in this trial
		gemcitabine hydrochloride
		triapine

5	Additional drug interventions recognized in this trial
		Gemcitabine

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Albert Einstein College of Medicine of Yeshiva University
		National Cancer Institute (NCI)